News Outlook blindsided as FDA blocks wet AMD drug once again Shares in Outlook Therapeutics lost more than half their value after the FDA turned down the company's marketing application for its wet AMD therapy.
News Bayer files 'safer, greener' MRI contrast agent in US FDA starts its review of Bayer's gadoquatrane, an MRI contrast agent that reduces the amount of gadolinium in medical imaging procedures.
Market Access Early strategic evidence planning is a key success factor in... As the European Union (EU) ushers in a new era of health technology regulation, pharmaceutical companies face both unprecedented challenges and opportunities.
News PTC stung by FDA decision not to approve rare disease drug It looks like PTC will have to carry out another trial of its drug for Friedreich ataxia before the FDA will consider approval.
News Court sides with Vanda over FDA's Hetlioz rejection A court has ordered the FDA to revisit a decision to turn down a drug for jet lag developed by Vanda, potentially setting a crucial legal precedent.
News Leaked MAHA draft signposts US health reform under Trump A leaked version of the Make America Healthy Again programme for the Trump administration has plenty for the pharma industry to stew over.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.